Calibrated serological techniques demonstrate significant different serum response rates to an oral killed cholera vaccine between Swedish and Nicaraguan children

Vaccination News Home Page

http://www.elsevier.com/gej-ng/10/42/35/80/25/43/abstract.html

Please note! As of 2002 online access to full-text articles is available to all readers whose library
  1. subscribes to Vaccine via ScienceDirect or
  2. has a print subscription to Vaccine and has registered for the corresponding ScienceDirect Web Editions.


Vaccine, Vol. 21 (1-2) (2002) pp. 138-145
© 2002 Elsevier Science Ltd. All rights reserved.
PII: S0264-410X(02)00348-1
 

Calibrated serological techniques demonstrate significant different serum response rates to an oral killed cholera vaccine between Swedish and Nicaraguan children

H.O. Hallander a, M. Paniagua b, F. Espinoza b, P. Askelöf c, E. Corrales b, M. Ringman a and J. Storsaeter d * jann.storsaeter@gsk.com

a Swedish Institute for Infectious Disease Control, Solna, Sweden
b Department of Microbiology, Universidad Nacional Autónoma de Nicaragua, León, Sweden
c SBL Vaccin AB, Solna, Sweden
d GlaxoSmithKline, P.O. Box 528, 183 25 Taby, Stockholm, Sweden

Received 16 January 2001; received in revised form 3 April 2002; accepted 8 July 2002

Abstract

Serum responses to oral cholera vaccines were assessed in three paediatric vaccine trials, two in León, Nicaragua and one in Stockholm, Sweden. A calibrated anti-cholera toxin B subunit (CTB) IgA ELISA was used together with an assay for vibriocidal antibodies. Swedish children had lower pre-vaccination levels of antibody, but serum responses were more pronounced in Swedish children than in Nicaraguan children. Post-vaccination levels of anti-toxin antibody were generally above those found after natural infections with enterotoxigenic Escherichia coli, that cross-reacts serologically with Vibrio cholerae. Adverse events seen after vaccination were generally mild and of little clinical significance.

Keywords: Serum response; Cholera vaccine; Technique

*Corresponding author. Tel.: +46-8-638-93-57; fax: +46-8-638-94-60.

Full text supplied by [ScienceDirect]

© Copyright 2002, Elsevier Science, All rights reserved.

Vaccination News Home Page

ALL INFORMATION, DATA, AND MATERIAL CONTAINED, PRESENTED, OR PROVIDED HERE IS FOR GENERAL INFORMATION PURPOSES ONLY AND IS NOT TO BE CONSTRUED AS REFLECTING THE KNOWLEDGE OR OPINIONS OF THE PUBLISHER, AND IS NOT TO BE CONSTRUED OR INTENDED AS PROVIDING MEDICAL OR LEGAL ADVICE.  THE DECISION WHETHER OR NOT TO VACCINATE IS AN IMPORTANT AND COMPLEX ISSUE AND SHOULD BE MADE BY YOU, AND YOU ALONE, IN CONSULTATION WITH YOUR HEALTH CARE PROVIDER.